INS and diabetes mellitus: Indeed, a cornerstone of current diabetes pharmacotherapy, the sulphonylurea receptor inhibitors (i.e., glibenclamide/glyburide), is aimed at antagonizing the hyperpolarizing IK,ATP current to facilitate β-cell depolarization and thereby potentiate insulin secretion.